Pharminent

Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation

Amgen (NASDAQ:AMGN) and Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered through Array’s proprietary platform that leverages Array’s expertise in chemistry and early lead development. http://www.worldpharmanews.com/amgen/4025-amgen-and-array-biopharma-announce-preclinical-license-and-collaboration-agreement-in-inflammation

Filed under: Inflammatory

Novartis’ psoriasis drug gets label boost

New label shows Cosentyx is superior to J&J’s rival in long-term.
The post Novartis’ psoriasis drug gets label boost appeared first on Pharmaphorum. https://pharmaphorum.com/news/novartis-cosentyx-gets-label-boost/

Filed under: Inflammatory

Eli Lilly arthritis drug outperforms Humira and receives NICE backing

Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be used on the NHS for the treatment of severe active forms of the disease which has not responded to intensive therapy with conventional disease-modifying antirheumatic drugs (DMARDs), it has emerged.
read more http://www.pharmafile.com/news/514503/eli-lilly-arthritis-drug-outperforms-humira-and-receives-nice-backing

Filed under: Arthritis

Lilly and NRAS launch arthritis awareness film campaign

Pharma firm’s ‘Behind The Smile’ initiative coincides with RA awareness week http://www.pmlive.com/pharma_news/lilly_and_nras_launch_arthritis_awareness_film_campaign_1196283

Filed under: Arthritis

AbbVie’s rheumatoid arthritis drug succeeds in late-stage trial

(Reuters) – U.S. drugmaker AbbVie Inc said on Wednesday its drug to treat moderate-to-severe rheumatoid arthritis met the main goal in a late-stage study.

http://www.reuters.com/article/us-abbvie-study-idUSKBN18Y1M9

Filed under: Arthritis

Sanofi and Regeneron score FDA approval for arthritis

The FDA has awarded Sanofi and Regeneron’s Kevzara (sarilumab) approval for the treatment of moderate to severely active rheumatoid arthritis (RA) in patients who have not responded to prior therapy.   
read more http://www.pharmafile.com/news/514154/sanofi-and-regeneron-score-fda-approval-arthritis

Filed under: Arthritis

EMA panel recommends nod for Sanofi, Regeneron’s arthritis drug

(Reuters) – A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron’s experimental drug to treat rheumatoid arthritis.

http://www.reuters.com/article/us-sanofi-fr-regeneron-pharms-ema-idUSKBN17N2BV

Filed under: Arthritis

New Assay May Lead to Better Rheumatoid Arthritis Treatment

NewsRheumatoid arthritis is a chronic inflammatory autoimmune disease that affects 1.5 million people in the United States.Contributed Author: NYUTopics: Disease Research http://www.dddmag.com/news/2017/03/new-assay-may-lead-better-rheumatoid-arthritis-treatment

Filed under: Arthritis

Amgen Signs Value-Based Deal for Enbrel

http://www.investopedia.com/news/amgen-signs-valuebased-deal-enbrel-amgn/

Filed under: Arthritis

Pfizer’s rheumatoid arthritis drug shows treatment benefit in combination but not alone

Pfizer’s phase 3B/4 study evaluating its Xeljanz (tofacitinib citrate) drug, a treatment for moderate to severe rheumatoid arthritis (RA), met its primary endpoint in combination with methotrexate (MTX) against AbbVie’s adalimumab (Humira) but didn’t meet the primary endpoint on its own. http://clinicaltrials.pharmaceutical-business-review.com/news/pfizers-rheumatoid-arthritis-drug-shows-treatment-benefit-in-combination-but-not-alone-170217-5742191

Filed under: Arthritis

EMA’s CHMP backs Pfizer’s Xeljanz for rheumatoid arthritis

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Pfizer’s Xeljanz to treat rheumatoid arthritis (RA). http://processandproduction.pharmaceutical-business-review.com/news/emas-chmp-backs-pfizers-xeljanz-for-rheumatoid-arthritis-300117-5726409

Filed under: Arthritis

GSK/J&J release how their drug measures up against Humira

GlaxoSmithKline and Janssen, part of Johnson & Johnson, released the results of their two Phase III trials exploring treatment options for adults suffering from active rheumatoid arthritis, in comparison with market leader Humira. The trial evaluated the drug sirukumab, co-developed by the two companies, which is a human anti-interleukin (IL)-6 monoclonal antibody.
read more http://www.pharmafile.com/news/511433/gskjj-release-how-their-drug-measure-against-humira

Filed under: Arthritis

Celgene’s Otezla hits primary endpoint in psoriatic arthritis study

Celgene has unveiled new data on its selective inhibitor of phosphodiesterase 4 (PDE4) Otezla (apremilast) which shows that the treatment met its primary endpoint, improving ACR20 response at week 16 versus placebo in patients suffering from active psoriatic arthritis.
read more http://www.pharmafile.com/news/511386/celgenes-otezla-hits-primary-endpoint-psoriatic-arthritis-study

Filed under: Arthritis

FDA delays approval of Sanofi and Regeneron’s rheumatoid arthritis drug sarilumab

The US Food and Drug Administration (FDA) has delayed approval for Sanofi and Regeneron Pharmaceuticals’ experimental treatment for rheumatoid arthritis (RA) due to manufacturing deficiencies. http://manufacturing.pharmaceutical-business-review.com/news/setback-for-sanofi-and-regeneron-as-fda-delays-ra-drug-approval-311016-5652570

Filed under: Arthritis

Pfizer anchoring inflammation hopes in Xeljanz

After a slow launch, the RA drug is picking up speed, leading the big pharma to invest in growing it further.  http://www.biopharmadive.com/news/pfizer-anchoring-inflammation-hopes-in-xeljanz/428643/

Filed under: Arthritis

NICE backs Celgene’s Otezla for psoriatic arthritis

Celgene’s Otezla is being backed for routine use on the National Health Service in England and Wales to treat psoriatic arthritis. http://www.pharmatimes.com/news/nice_backs_celgenes_otezla_for_psoriatic_arthritis_1160072

Filed under: Arthritis

AstraZeneca licenses inflammatory disease candidate to Allergan

LONDON (Reuters) – Britain’s AstraZeneca said it had licensed a potential medicine for inflammatory diseases to Allergan for an upfront payment of $250 million and potential additional payments of up to $1.27 billion.

http://www.reuters.com/article/us-astrazeneca-allergan-inflammatory-dru-idUSKCN1230FL

Filed under: Inflammatory

J&J psoriasis drug tops placebo, Humira in late stage study

http://finance.yahoo.com/news/j-j-psoriasis-drug-tops-060002087.html

Filed under: Inflammatory

Janssen Biotech files US regulatory application for Sirukumab in rheumatoid arthritis

Janssen Biotech is seeking approval for sirukumab in the US to treat adults with moderately to severely active rheumatoid arthritis (RA). http://processandproduction.pharmaceutical-business-review.com/news/janssen-biotech-files-us-regulatory-application-for-sirukumab-in-rheumatoid-arthritis-260916-5014980

Filed under: Arthritis

European Commission Approves Bristol-Myers Squibb’s ORENCIA® (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate

[Business Wire] – Bristol-Myers Squibb Company today announced that the European Commission has approved ORENCIA® intravenous infusion and subcutaneous injection, in combination with methotrexate , for the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with MTX. http://finance.yahoo.com/news/european-commission-approves-bristol-myers-105900966.html

Filed under: Arthritis

Categories